NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Oxcia AB

Oxcia AB

Private
StockholmHealthcare & Life Scienceshttps://oxcia.com/

Last Round

Private Equity

Jun 27, 2025

Est. Valuation

$15.81M

Total Funding Raised

$5.73M

Company Overview

Oxcia AB is a biotechnology company that develops innovative treatments for cancer and inflammatory diseases by targeting oxidative DNA damage and DNA Damage Response pathways.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoveryDNA damage responseDDRoxidative stresssmall molecule inhibitorsoncologycancer researchfibrosis treatmentclinical-stage biotechdrug developmentMTH1 inhibitorOGG1 inhibitorbiotech startuptherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Oxcia AB Comps

Public and private peers based on sector, stage, and business model.

Oxcia AB comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Oxcia AB Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private EquityJun 27, 2025
VC RoundOct 10, 2023
GrantApr 1, 2023
GrantFeb 24, 2023
Private PlacementFeb 1, 2022
Private Placement
Mar 26, 2021

Oxcia AB Investors

Notable investors and investment history

Oxcia AB investors
InvestorRounds
European Innovation Council FundGrant
VinnovaGrant
SwelifeGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2023

    $290K grant received from Medtech4Health, Swelife, and Vinnova.

  • Feb 1, 2022

    Raised $2.21M in a private placement round.

Oxcia AB Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Oxcia AB Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Oxcia AB's valuation, stock price, and market status.

Firmographic Details

HeadquartersStockholm
Employee Range12
Year Founded2014
Last FundingJun 27, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.